284 related articles for article (PubMed ID: 27213343)
1. A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.
Longacre M; Snyder NA; Housman G; Leary M; Lapinska K; Heerboth S; Willbanks A; Sarkar S
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213343
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.
Greville G; McCann A; Rudd PM; Saldova R
Epigenetics; 2016 Dec; 11(12):845-857. PubMed ID: 27689695
[TBL] [Abstract][Full Text] [Related]
3. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.
Bapat SA; Jin V; Berry N; Balch C; Sharma N; Kurrey N; Zhang S; Fang F; Lan X; Li M; Kennedy B; Bigsby RM; Huang TH; Nephew KP
Epigenetics; 2010; 5(8):716-29. PubMed ID: 20676026
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer and ovarian cancer genetics.
Edlich RF; Winters KL; Lin KY
J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
Trnkova L; Buocikova V; Mego M; Cumova A; Burikova M; Bohac M; Miklikova S; Cihova M; Smolkova B
Biomed Pharmacother; 2024 May; 174():116559. PubMed ID: 38603889
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.
Matei D; Nephew KP
Cancer Res; 2020 Sep; 80(18):3775-3785. PubMed ID: 32381656
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Press JZ; De Luca A; Boyd N; Young S; Troussard A; Ridge Y; Kaurah P; Kalloger SE; Blood KA; Smith M; Spellman PT; Wang Y; Miller DM; Horsman D; Faham M; Gilks CB; Gray J; Huntsman DG
BMC Cancer; 2008 Jan; 8():17. PubMed ID: 18208621
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
Borley J; Brown R
Ann Med; 2015; 47(5):359-69. PubMed ID: 26158617
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modulation of BRCA-1 and MGMT genes, and histones H4 and H3 are associated with breast tumors.
Paydar P; Asadikaram G; Nejad HZ; Akbari H; Abolhassani M; Moazed V; Nematollahi MH; Ebrahimi G; Fallah H
J Cell Biochem; 2019 Aug; 120(8):13726-13736. PubMed ID: 30938887
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
12. TP53 Mutations in Breast and Ovarian Cancer.
Silwal-Pandit L; Langerød A; Børresen-Dale AL
Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27815305
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
[TBL] [Abstract][Full Text] [Related]
14. Minireview: epigenetic changes in ovarian cancer.
Balch C; Fang F; Matei DE; Huang TH; Nephew KP
Endocrinology; 2009 Sep; 150(9):4003-11. PubMed ID: 19574400
[TBL] [Abstract][Full Text] [Related]
15. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Xu X; Lv YG; Yan CY; Yi J; Ling R
Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.
Wang Y; Huang Z; Li B; Liu L; Huang C
Front Endocrinol (Lausanne); 2022; 13():863541. PubMed ID: 35620395
[TBL] [Abstract][Full Text] [Related]
17. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.
Chapman-Rothe N; Curry E; Zeller C; Liber D; Stronach E; Gabra H; Ghaem-Maghami S; Brown R
Oncogene; 2013 Sep; 32(38):4586-92. PubMed ID: 23128397
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 methylation: a significant role in tumour development?
Catteau A; Morris JR
Semin Cancer Biol; 2002 Oct; 12(5):359-371. PubMed ID: 12191635
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
